Eisai Slams DEA Over Delay In Scheduling Seizure Med
A U.S. unit of Japanese pharmaceutical firm Eisai Co. Ltd. launched an appeal in the D.C. Circuit on Monday to order the U.S. Drug Enforcement Administration to schedule its epilepsy drug Fycompa,...To view the full article, register now.
Already a subscriber? Click here to view full article